By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Plasticell today said that it has completed a £3.5 million ($5.6 million) two-part equity financing.

The London-based maker of high-throughput technologies for directed stem cell differentiation, said that it will use the funds to expand its business development and marketing activities as it attempts to grow its customer base. The company has developed the CombiCult technology, which is used to develop stem cell differentiation protocols.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: association between genome-wide homozygosity and traits like height and cognitive ability, improved CRISPR-Cas9 editing, and more.

A survey examines how age, political leanings, and more influence how Americans view certain scientific topics, the Associated Press reports.

A researcher who pleaded guilty to making false statements in research reports has been sentenced to four and a half years in prison and must pay $7.2 million back to the NIH.

The BabySeq project to study the risks and benefits of sequencing newborns is underway.